Estudo PRIMA: niraparib demonstra benefício na PFS a longo prazo no tratamento de 1.ª linha do cancro do ovário
PARP Inhibitors. - ppt download
Niraparib in Patients With Newly Diagnosed Advanced Ovarian BRCAm Cancer: A Post Hoc Analysis of the PRIMA/ENGOT-OV26/GOG-3012 T
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
PRIMA study design. CR complete response, PR partial response, PFS... | Download Scientific Diagram
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Efficacy of niraparib in the PRIMA phase III trial | Download Scientific Diagram
PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian Cancer
PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets - The ASCO Post
Zejula (Niraparib) First PARP Inhibitor Approved for First-Line Maintenance Therapy in All Women with Advanced Ovarian Cancer, Regardless of Biomarker Status
Personalized Dosing of Niraparib in Ovarian Cancer - YouTube
Predictors of Long-term Progression-Free Survival in Niraparib-Treated Patients in the PRIMA/ENGOT-OV16/GOG-3012 Study
PARP inhibitors as first-line maintenance treatment for ovarian cancer: Translating the latest data to clinical practice - touchONCOLOGY
Treatment Considerations With Niraparib
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer | Targeted Oncology
An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions | Oncology and Therapy
CME; Niraparib, Olaparib, bevacizumab, PRIMA trial, PAOLO-1
TESARO Pioneers Summit - ppt download
Niraparib Efficacy and Safety in Patients with BRCA-Mutated (BRCAm) Ovarian Cancer: Results from Three Phase 3 Niraparib Trials
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - European Journal of
PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets - The ASCO Post
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - ScienceDirect
Zejula (niraparib) com resultados positivos como terapêutica de primeira linha | Netfarma
Inhibidores de PARP en primera línea de cáncer de ovario | PPT
Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5) -
